Pegylated interferon alpha 2b (PEG-IFN) plus ribavirin (RBV) versus pegylated interferon alpha 2b for chronic hepatitis C in HIV patients

被引：0
|
作者：
Cargnel, A
Angeli, E
Mainini, A
Gubertini, G
Giorgi, R
Orlando, G
Duca, P
机构：
来源：
GASTROENTEROLOGY | 2003年 / 124卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(03)83871-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A766 / A766
页数：1
相关论文
共 50 条
  • [21] Pegylated interferon alpha 2b induces less thyroid dysfunction than standard interferon alpha 2b in the treatment of chronic hepatitis C
    Patel, Y
    Chapalamadugu, R
    Ramdhaney, S
    Baradarian, R
    Iswara, K
    Tenner, S
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (09): : S87 - S88
  • [22] Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C A Meta-Analysis
    Flori, Nicolas
    Funakoshi, Natalie
    Duny, Yohan
    Valats, Jean-Christophe
    Bismuth, Michael
    Christophorou, Dimitri
    Daures, Jean-Pierre
    Blanc, Pierre
    DRUGS, 2013, 73 (03) : 263 - 277
  • [23] Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients
    Lee, Seok
    Kim, In Hee
    Kim, Seong Hun
    Kim, Sang Wook
    Lee, Seung Ok
    Lee, Soo Teik
    Kim, Dae Ghon
    Lee, Chang Seop
    Choi, Chang Soo
    Cho, Eun Young
    Kim, Haak Cheoul
    INTERVIROLOGY, 2010, 53 (03) : 146 - 153
  • [24] Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase
    Kainuma, Mosaburo
    Furusyo, Norihiro
    Azuma, Koichi
    Kajiwara, Eiji
    Takahashi, Kazuhiro
    Nomura, Hideyuki
    Tanabe, Yuichi
    Satoh, Takeaki
    Maruyama, Toshihiro
    Nakamuta, Makoto
    Kotoh, Kazuhiro
    Shimoda, Shinji
    Hayashi, Jun
    HEPATOLOGY RESEARCH, 2012, 42 (01) : 33 - 41
  • [25] An open, multicenter, randomized trial comparing pegylated interferon alpha-2b (PEG-IFN) plus ribavirin (RBV) versus PEG-IFN for treatment of HIV/HCV co-infected patients.
    Cargnel, A
    Angeli, E
    Casella, A
    Gubertini, G
    Mainini, A
    Orlando, G
    Duca, P
    HEPATOLOGY, 2002, 36 (04) : 363A - 363A
  • [26] Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C - Reply
    Fabrizi, F
    Martin, P
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (01) : 124 - 124
  • [27] Response to interferon alpha 2B plus ribavirin in hepatitis C infected patients who failed interferon alpha 2B monotherapy.
    King, JW
    Favrot, DR
    Shakhashiro, A
    Gholson, CF
    Balart, LA
    Achord, J
    Kirkikis, JA
    Lyles, WE
    Hollier, JD
    Srinivas, D
    HEPATOLOGY, 1998, 28 (04) : 708A - 708A
  • [28] African-american patients with chronic hepatitis c respond similarly to PEG-IFN alpha 2a and ribavirin as compared to PEG-IFN alpha 2b and ribavirin
    Khan, Afreen
    Mutchnick, Milton
    Ehrinpreis, Murray
    Siddiqui, Firdous
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S124 - S124
  • [29] Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C
    Nomura, H.
    Miyagi, Y.
    Tanimoto, H.
    Ishibashi, H.
    JOURNAL OF VIRAL HEPATITIS, 2009, 16 (05) : 346 - 351
  • [30] Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis CA Meta-Analysis
    Nicolas Flori
    Natalie Funakoshi
    Yohan Duny
    Jean-Christophe Valats
    Michael Bismuth
    Dimitri Christophorou
    Jean-Pierre Daurès
    Pierre Blanc
    Drugs, 2013, 73 : 263 - 277
12345